ESMO 2026 | OrigAMI-4: amivantamab, pembrolizumab, and carboplatin in head and neck cancer
Paul Swiecicki, MD, University of Michigan, Ann Arbor, MI, discusses results from cohort 5 of the Phase Ib/II OrigAMI-4 (NCT06385080) study evaluating subcutaneous amivantamab plus pembrolizumab and carboplatin as first-line therapy for PD-L1-positive recurrent or metastatic head and neck squamous cell carcinoma. The combination achieved a high response rate in human papillomavirus (HPV)-unrelated disease, with most responses ongoing, while activity was more modest in HPV-positive oropharyngeal cancer. Safety was consistent with the individual agents, with few administration-related reactions This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah, OrigAMI-4 study is a basket study about amivantamab and recurrent metastatic head and neck cancer. There’s multiple cohorts including amivantamab monotherapy and platinum refractory and ICI refractory setting, amivantamab plus Taxol, amivantamabplus platinum and with immune checkpoint inhibitor and that’s cohort five which we’re discussing here at ASCO today...
Yeah, OrigAMI-4 study is a basket study about amivantamab and recurrent metastatic head and neck cancer. There’s multiple cohorts including amivantamab monotherapy and platinum refractory and ICI refractory setting, amivantamab plus Taxol, amivantamabplus platinum and with immune checkpoint inhibitor and that’s cohort five which we’re discussing here at ASCO today. Now cohort five was the first one to evaluate first line platinum plus Pembro plus amivantamab in first line metastatic head and neck cancer. Of the 30 patients enrolled, 29 were eligible, and of that we saw an astounding 66% response rate overall. The study enrolled both HPV positive and HPV negative patients. In the HPV unrelated population, we saw a response rate of 77%. Even more interesting is the median progression-free survival was 7.7 months, and the median overall survival at this point was not reached. At 12 months, 70% of these patients are alive, and so this data compares very strongly compared to historical controls such as Keynote 048.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
